ClinicalTrials.govpublic full text
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
colorectal cancer metastatic, microsatellite stable (mss) colorectal cancer (crc), pd-1/ctla-4, ql1706, bevacizumab, folfiri, second-line, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 830111
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.